4D Molecular Therapeutics, Inc. (FDMT) Operating margin 2019–2025
4D Molecular Therapeutics, Inc. (FDMT) operating margin by fiscal year — reported operating income divided by reported revenue.
-187.2%FY2025 · since FY2019: -729.4% → -187.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -187.2% | +507491.1 pp |
| FY2024 | -507678.4% | -507133.7 pp |
| FY2023 | -544.6% | +2971.9 pp |
| FY2022 | -3516.5% | -3121.1 pp |
| FY2021 | -395.5% | +28.6 pp |
| FY2020 | -424.0% | +305.3 pp |
| FY2019 | -729.4% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice